GammaVibe Daily
How bots are rigging prediction markets
As prediction markets mainstream into pop culture, a new wave of bot operations is rigging streaming metrics. Kritos is building the tamper-proof oracle layer to stop it.
GammaVibe Daily
APIs built for silicon, not carbon
As software developers rethink apps for AI agents, a new infrastructure layer is emerging to solve the LLM token tax.
GammaVibe Daily
Who actually owns your digital games?
As physical media vanishes, gamers are realizing their digital collections are just temporary rentals. Here is how Rootstock plans to fix it.
GammaVibe Daily
How bots conquered the box office
Standard CAPTCHAs are dead. It's time for invisible behavioral biometrics to save our sanity—and our ticket drops.
GammaVibe Daily
Wealth transfer meets the annuity boom
How upcoming inheritance tax overhauls are turning boring annuities into the ultimate high-net-worth estate planning tool.
GammaVibe Daily
Industrial giants meet their digital heirs
How a quiet demographic shift in Germany and Portugal is opening a massive opportunity for tech-forward operators.
GammaVibe Daily
The new golf is played with tiles
How Mahjong is quietly becoming the next high-value relationship network.
GammaVibe Daily
Hunting your forgotten SaaS tokens
Why years-old OAuth credentials are the modern enterprise's biggest blindspot, and the startup cleaning up the sprawl.
GammaVibe Daily
The great estrogen patch scramble
Hormone prescription demand has surged by 162%, leaving specialized clinics in a procurement nightmare. Here is how B2B software solves it.
GammaVibe Daily
Routing space lasers around clouds
Space telemetry is shifting to optical downlinks, but weather is still undefeated. Here is how we build the routing layer.
GammaVibe Daily
E-paper is coming for your walls
Why consumers are swapping glowing pixels for matte, ambient e-paper dashboards, and the SaaS opportunity behind the hardware.
GammaVibe Daily
The FDA's quiet shift to synthetic patients
A regulatory pivot is unlocking a multi-billion dollar shortcut for rare disease drug development. Meet Kohrt.